Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Patent
1995-01-30
1996-11-26
Daus, Donald G.
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
C07D48910
Patent
active
055787258
ABSTRACT:
Compounds are provided of the formula: ##STR1## wherein R.sup.1 is (C.sub.1 -C.sub.5)alkyl, C.sub.3 -C.sub.6 (cycloalkyl)alkyl, C.sub.5 -C.sub.7 (cycloalkenyl)alkyl, (C.sub.6 -C.sub.12)aryl, (C.sub.6 -C.sub.12)aralkyl, trans(C.sub.4 -C.sub.5)alkenyl, allyl or furan-2-ylalkyl, R.sup.2 is H, OH or O.sub.2 C(C.sub.1 -C.sub.5)alkyl; R.sup.3 is H, (C.sub.6 -C.sub.10)aralkyl, (C.sub.1 -C.sub.5)alky or (C.sub.1 -C.sub.5)alkylCO; X is O, S or NY, wherein Y is H, benzyl or (C.sub.1 -C.sub.5)alkyl; R is CH(Z)CO.sub.2 Y, wherein Z is H, CH.sub.2 CO.sub.2 Y or (CH.sub.2).sub.n N(R.sup.4)(R.sup.5), wherein n is 1-5 and R.sup.4 and R.sup.5 are individually H, (C.sub.1 -C.sub.4)alkyl, phenyl, (C.dbd.NH)NH.sub.2, benzyloxycarbonyl or (C.dbd.NHNO.sub.2); and the pharmaceutically acceptable salts thereof.
REFERENCES:
patent: 4362870 (1982-12-01), Portoghese
patent: 4401672 (1983-08-01), Portoghese
patent: 4440932 (1984-04-01), Kotick et al.
patent: 4649200 (1987-03-01), Portoghese et al.
patent: 4806556 (1989-02-01), Portoghese
patent: 4816586 (1989-03-01), Portoghese
patent: 5223507 (1993-06-01), Dappen
patent: 5225417 (1993-07-01), Dappen
patent: 5244904 (1993-09-01), Nagase et al.
patent: 5332818 (1994-07-01), Nagase
patent: 5352680 (1994-10-01), Portoghese et al.
patent: 5354863 (1994-10-01), Dappen eta l.
patent: 5436249 (1995-07-01), Dappen
patent: 5457208 (1995-10-01), Portoghese et al.
patent: 5464841 (1995-11-01), Portoghese
E. E. Abdelhamid et al., "Selective Blockage of Delta Opioid Receptors Prevents the Development of Morphine Tolerance and Dependence in Mice," The Journal of Pharmacology and Experimental Therapeutics, 258, 299-303 (1991).
K. Arakawa et al., "Immunosuppressive Effect of .delta.-Opioid Receptor Antagonist on Xenogenic Mixed Lymphocyte Reaction," Transplantation Proceedings, 24, 696-697 (Apr., 1992).
K. Arakawa et al., "The Immunosuppresive Effect of .delta.-Opioid Receptor Anagonist on Rat Renal Allograft Survival," Transplant, 53, 951-953 (1992).
K. Arakawa et al., "Delta Opioid Receptor Anatagonist for Immunosuppression After Rat Kidney Transplantation," International Narcotics Research Conference, p. 102, Abstract No. 018 (Jun. 24, 1992).
S. Botros et al., "Opioid Agonist and Antagonist Activities of Peripherally Selective Derivatives of Naltrexamine and Oxymorphamine," J. Med. Chem., 32, 2068-2071 (1989).
D. R. Brown et al., "The Use of Quarternary Narcotic Antagonists in Opiate Research," Neuropharmacology, 24, 181-191 (1985).
E. J. Drower et al., "Selective Antagonism by Naltrindole of the Antinociceptive Effects of the Delta Opioid Agonist Cyclic [D-Penicillamine.sup.2 -D-Penicillamine.sup.5 ] Enkephalin in the Rat," The Journal of Pharmacology and Experimental Therapeutics, 259, 725-731, (1991).
M. Erez et al., "Narcotic Antagonist Potency of Bivalent Ligands which Contain .beta.-Naltrexamine. Evidence for Bridging Between Proximal Recognition Sites," J. Med. Chem. 25, 847-849 (1982).
J. H. Jaffe et al., "Opioid Analgestics and Antagonists," In:The Pharmacological Basis of Therapeutics, A. G. Gilman et al., (eds.) Peragamon Press, New York, Chapter 21, pp. 485-521 (1990).
H. Kataoka, "Novel Indolomorphinan Derivatives," Abstract No. 120798v, Chemical Abstracts, 73, 398 (1970).
W. R. Martin, "Pharmacology of Opioids," Pharmacological Reviews, 35, 283-323, (Dec. 1983).
S. L. Olmsted et al., "A Remarkable Change of Opioid Receptor Selectivity on the Attachment of a Peptidomimetnic .kappa. Address Element to the .delta. Antagonist, Natrindole: 5'-[N.sup.2 -Alkylamidino) methyl]naltrindole Derivatives as a Novel Class of .kappa. Opioid Receptor Antagonists," Journal of Medicinal Chemistry, 36, 179-180 (1993).
P. S. Portoghese et al., "A Novel Opioid Receptor Site Directed Alkylating Agent with Irreversible Narcotic Antagonistic and Reversible Agonistic Activities," J. Med. Chem., 23, 233-234 (1980).
P. S. Portoghese et al., "Tena, A Selective Kappa Opioid Receptor Antagonist," Life Sciences, 36, 801-805 (1985).
P. S. Portoghese et al., "Application of the Message-Address Concept in the Design of Highly Potent and Selective Non-Peptide .delta. Opioid Receptor Antagonists," J. Med. Chem., 31, 281-282 (Feb. 1988).
P. S. Portoghese et al., "Only One Pharmacophore is Required for the .kappa. Opioid Antagonist Selectivity of Norbinaltorphimine," J. Med. Chem., 31, 1344-1347 (1988).
P. S. Portoghese et al., "Naltindole, a highly selective and potent non-peptide .delta. opioid receptor antagonist," European J. of Pharma., 146, 185-186 (1988).
P. S. Portoghese, "Bivalent ligands and the message-address concept in the design of selective opioid receptor antagonists," Trends Pharmacol. Sci., 10, 230-235 (Jun., 1989).
P. S. Portoghese et al., "Natrindole 5'-Isothiocyanate: A Nonequillibrium, Highly Selective .delta. Opioid Receptor Antagonist," J. Med. Chem., 33, 1547-1548 (1990).
P. S. Portoghese et al., "Design of Peptidomimetic .delta. Opioid Receptor Antagonists Using the Message-Address Concept," J. Med. Chem., 33, 1714-1720 (1990).
P. S. Portoghese et al., "Role of Spacer in Conferring .kappa. Opioid Receptor Selectivity to Bivalent Ligands Related to Norbinaltorphimine," J. of Med. Chem., 34, 1292-1296 (1991).
L. D. Reid et al., "Naltrindole, An Opioid Delta Receptor Antagonist, Blocks Cocaine-Induced Facilitation of Responding for Rewarding Brain Stimulation," Life Sciences, 52, PL67-71 (1993).
C. F. C. Smith, "16-Me Cyprenorphine (RX 8008M): A Potent Opioid Antagonist with some .delta. Selectivity," Life Sciences, 40, 267-274 (1987).
M. Sofuoglu et al., "Differential Antagonism of Delta Opioid Agonists by Naltrindole and its Benzofuran Analog (NTB) in Mice: Evidence for Delta Opioid Receptor Subtypes," The J. of Pharma. and Experimental Thera., 257, 676-680 (1991).
A. E. Takemori et al., "The Irreverible Narcotic Antagonist and Reversible Agonistic Properties of the Fumaramate Methyl Ester Derivative of Naltrexone," Eur. J. of Pharma., 70, 445-451 (1981).
A. E. Takemori et al., "Evidence for the Interaction of Morphine with Kappa and Delta Opioid Receptors to Induce Analgesia in .beta.-Funaltrexamine-Treated Mice," J. of Pharm. and Experimental Thera., 243, 91-94 (1987).
A. E. Takemori et al., "Nor-Binaltorphimine, A Highly Selective Kappa-Opioid Antagonist in Analgesic and Receptor Binding Assays," J. of Pharma. and Exper. Thera., 246, 255-258 (1988).
S. J. Ward et al., "Improved Assays for the Assessment of .kappa.- and .delta.-Properties of Opioid Ligands," Eur. J. of Pharma., 85, 163-170 (1982).
M. S. Yamamura et al., "Characterization of [.sup.3 H]Naltrindole Binding to Delta Opioid Receptors in Rat Brain," Life Sciences, 50, PL 119-124 (1992).
Farouz-Grant Francine S.
Portoghese Philip S.
Daus Donald G.
Regents of the University of Minnesota
LandOfFree
Delta opioid receptor antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Delta opioid receptor antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Delta opioid receptor antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1974106